Apellis Completes $404.2 Million Follow-On Offering

Healthcare

Apellis follow-on offering


Summary

Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ-GS: APLS) recently completed an underwritten public offering of 10,925,000 shares of its common stock at a price to the public of $37.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,425,000 shares of common stock. The gross proceeds to Apellis from the offering are expected to be approximately $404.2 million.

Baird served as a lead manager on this offering.

About

Apellis is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, Apellis aims to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology and nephrology. Apellis Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
CONTACT US TO LEARN MORE
Healthcare

Apellis follow-on offering

Date
January 2020
Company
Apellis Pharmaceuticals, Inc.
Transaction
Equity Capital Markets
Sectors
Healthcare
Verticals
Biotechnology & Pharmaceuticals
Target Geography
North America

Share